Press Release / NEWS / IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-T

NEWS

26/092026
2026 IMS | IASO Bio Presented FUCASO China Real-World Data
26/092026
2026 IMS | IASO Bio Presented First-in-Human Data of BCMA-Targeted In Vivo CAR-T Cell Therapy Product IASO206
25/092026
2026 IMS | IASO Bio Presents First-in-Human Phase 1 Data of RD140, a Fully Human BCMA/GPRC5D Dual-Targeted FasT CAR-T

252026-09

2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio’s FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression
162026-09

IASO Bio’s CD20-Targeted In Vivo CAR-T Therapy IASO208 Receives FDA IND Clearance
142026-09

IASO Bio Announces Completion of Enrollment in FUMANBA-3 Phase III Registrational Study of Equecabtagene Autoleucel for Second- and Third-Line Multiple Myeloma
212026-08

IASO Bio's Registration Application for FUCASO® (equecabtagene autoleucel) Accepted by Australia's TGA
302026-07

Umoja Biopharma announces United States clinical trial initiation of industry’s first known CD22-targeted In Vivo CAR-T Therapy, developed in collaboration with IASO Bio
132026-08

IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics
182026-06

IASO Bio Announces NDA Approval of Equecabtagene Autoleucel by the Singapore Health Sciences Authority (HSA) for the Treatment of Relapsed or Refractory Multiple Myeloma, Marking a Key Milestone in International Commercialization

Copyright © 2023 南京驯鹿生物技术股份有限公司　　　　苏ICP备2021047135号　　　　 Privacy Policy　|　Terms of Use